Cardiovascular Disease Risk Factors in Chronic Kidney Disease: Overall Burden and Rates of Treatment and Control | Cardiology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.177.17. Please contact the publisher to request reinstatement.
1.
Anavekar  NSMcMurray  JJVelazquez  EJ  et al.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.  N Engl J Med 2004;3511285- 1295PubMedGoogle ScholarCrossref
2.
Foley  RNParfrey  PSSarnak  MJ Clinical epidemiology of cardiovascular disease in chronic renal disease.  Am J Kidney Dis 1998;32 ((suppl 3)) S112- S119PubMedGoogle ScholarCrossref
3.
Go  ASChertow  GMFan  DMcCulloch  CEHsu  CY Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.  N Engl J Med 2004;3511296- 1305PubMedGoogle ScholarCrossref
4.
Manjunath  GTighiouart  HIbrahim  H  et al.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.  J Am Coll Cardiol 2003;4147- 55PubMedGoogle ScholarCrossref
5.
Coresh  JAstor  BCGreene  TEknoyan  GLevey  AS Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.  Am J Kidney Dis 2003;411- 12PubMedGoogle ScholarCrossref
6.
U.S. Renal Data System, USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States.  Bethesda, Md National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health2002;
7.
Baigent  CBurbury  KWheeler  D Premature cardiovascular disease in chronic renal failure.  Lancet 2000;356147- 152PubMedGoogle ScholarCrossref
8.
Bleyer  AJShemanski  LRBurke  GLHansen  KJAppel  RG Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population.  Kidney Int 2000;572072- 2079PubMedGoogle ScholarCrossref
9.
Fox  CSLarson  MGLeip  EP  et al.  Predictors of new-onset kidney disease in a community-based population.  JAMA 2004;291844- 850PubMedGoogle ScholarCrossref
10.
Manttari  MTiula  EAlikoski  TManninen  V Effects of hypertension and dyslipidemia on the decline in renal function.  Hypertension 1995;26670- 675PubMedGoogle ScholarCrossref
11.
Muntner  PCoresh  JSmith  JCEckfeldt  JKlag  MJ Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.  Kidney Int 2000;58293- 301PubMedGoogle ScholarCrossref
12.
Tozawa  MIseki  KIseki  C  et al.  Influence of smoking and obesity on the development of proteinuria.  Kidney Int 2002;62956- 962PubMedGoogle ScholarCrossref
13.
Cheung  AKSarnak  MJYan  G  et al.  Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients.  Kidney Int 2000;58353- 362PubMedGoogle ScholarCrossref
14.
Longenecker  JCCoresh  JPowe  NR  et al.  Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.  J Am Soc Nephrol 2002;131918- 1927PubMedGoogle ScholarCrossref
15.
Tonelli  MBohm  CPandeya  S  et al.  Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.  Am J Kidney Dis 2001;37484- 489PubMedGoogle ScholarCrossref
16.
Wheeler  DCTownend  JNLandray  MJ Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study.  Kidney Int Suppl May 2003;S201- S203PubMedGoogle Scholar
17.
Fox  CSLongenecker  JCPowe  NR  et al. CHOICE Study, Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients.  Clin Nephrol 2004;61299- 307PubMedGoogle ScholarCrossref
18.
Berger  AKDuval  SKrumholz  HM Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.  J Am Coll Cardiol 2003;42201- 208PubMedGoogle ScholarCrossref
19.
Ezekowitz  JMcAlister  FAHumphries  KH  et al. APPROACH Investigators, The association among renal insufficiency, pharmacotherapy, and outcomes in 6427 patients with heart failure and coronary artery disease.  J Am Coll Cardiol 2004;441587- 1592PubMedGoogle ScholarCrossref
20.
Gibney  EMCasebeer  AWSchooley  LM  et al.  Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a National Veterans Administration study.  Kidney Int 2005;68826- 832PubMedGoogle Scholar
21.
Dawber  TRKannel  WBLyell  LP An approach to longitudinal studies in a community: the Framingham Study.  Ann N Y Acad Sci 1963;107539- 556PubMedGoogle ScholarCrossref
22.
Kannel  WBFeinleib  MMcNamara  PMGarrison  RJCastelli  WP An investigation of coronary heart disease in families: the Framingham Offspring Study.  Am J Epidemiol 1979;110281- 290PubMedGoogle Scholar
23.
National Kidney Foundation, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.  Am J Kidney Dis 2002;39 ((suppl 1)) S1- S266PubMedGoogle Scholar
24.
Levey  ASBosch  JPLewis  JB  et al. Modification of Diet in Renal Disease Study Group, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.  Ann Intern Med 1999;130461- 470PubMedGoogle ScholarCrossref
25.
Coresh  JAstor  BCMcQuillan  G  et al.  Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate.  Am J Kidney Dis 2002;39920- 929PubMedGoogle ScholarCrossref
26.
Wilson  PWD’Agostino  RBLevy  DBelanger  AMSilbershatz  HKannel  WB Prediction of coronary heart disease using risk factor categories.  Circulation 1998;971837- 1847PubMedGoogle ScholarCrossref
27.
Cupples  LAD’Agastino  RB Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Study, 30-year follow-up. Kannel  WBWolf  PAGarrison  RJeds The Framingham Heart Study an Epidemiologic Investigation of Cardiovascular Disease. Washington, DC National Institutes os Health1987;87- 203Google Scholar
28.
Chobanian  AVBakris  GLBlack  HR  et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.  JAMA 2003;2892560- 2572[published correction appears in JAMA. 2003;290:197]PubMedGoogle ScholarCrossref
29.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA 2001;2852486- 2497PubMedGoogle ScholarCrossref
30.
American Diabetes Association, Standards of medical care in diabetes.  Diabetes Care 2005;28 ((suppl 1)) S4- S36[published correction appears in Diabetes Care. 2005;28:990]PubMedGoogle ScholarCrossref
31.
Hosmer  DW  JrLemeshow  S Applied Logistic Regression.  New York, NY John Wiley & Sons Inc1989;
32.
SAS Institute Inc, SAS/STAT User's Guide: Version 8.  Cary, NC SAS Institute Inc2000;
33.
Peralta  CAHicks  LSChertow  GM  et al.  Control of hypertension in adults with chronic kidney disease in the United States.  Hypertension 2005;451119- 1124PubMedGoogle ScholarCrossref
34.
Bakris  GLWeir  MR Angiotensin-converting enzyme inhibitor–associated elevations in serum creatinine: is this a cause for concern?  Arch Intern Med 2000;160685- 693PubMedGoogle ScholarCrossref
35.
Burkhardt  HBruckner  DGladisch  R Risk factors of worsening renal function in hospitalized elderly patients.  J Nephrol 2005;18166- 173PubMedGoogle Scholar
36.
Pahor  MShorr  RISomes  GW  et al.  Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the Systolic Hypertension in the Elderly Program.  Arch Intern Med 1998;1581340- 1345PubMedGoogle ScholarCrossref
37.
Klag  MJWhelton  PKRandall  BL  et al.  Blood pressure and end-stage renal disease in men.  N Engl J Med 1996;33413- 18PubMedGoogle ScholarCrossref
38.
Perry  HM  JrMiller  JPFornoff  JR  et al.  Early predictors of 15-year end-stage renal disease in hypertensive patients.  Hypertension 1995;25587- 594PubMedGoogle ScholarCrossref
39.
Young  JHKlag  MJMuntner  P  et al.  Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP).  J Am Soc Nephrol 2002;132776- 2782PubMedGoogle ScholarCrossref
40.
Ruggenenti  PPerna  ALoriga  G  et al. REIN-2 Study Group, Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.  Lancet 2005;365939- 946PubMedGoogle ScholarCrossref
41.
Sarnak  MJGreene  TWang  X  et al.  The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study.  Ann Intern Med 2005;142342- 351PubMedGoogle ScholarCrossref
42.
Wright  JT  JrBakris  GGreene  T  et al. African American Study of Kidney Disease and Hypertension Study Group, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.  JAMA 2002;2882421- 2431[published correction appears in JAMA. 2006;295:2726]PubMedGoogle ScholarCrossref
43.
Tonelli  MMoye  LSacks  FMCole  TCurhan  GCCholesterol and Recurrent Events Trial Investigators, Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.  J Am Soc Nephrol 2003;141605- 1613PubMedGoogle ScholarCrossref
44.
Tonelli  MIsles  CCraven  T  et al.  Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease.  Circulation 2005;112171- 178PubMedGoogle ScholarCrossref
45.
Tonelli  MCollins  DRobins  SBloomfield  HCurhan  GCVeterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators, Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.  Kidney Int 2004;661123- 1130PubMedGoogle ScholarCrossref
46.
Tonelli  MIsles  CCurhan  GC  et al.  Effect of pravastatin on cardiovascular events in people with chronic kidney disease.  Circulation 2004;1101557- 1563PubMedGoogle ScholarCrossref
47.
Wanner  CKrane  VMarz  W  et al. German Diabetes and Dialysis Study Investigators, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [published correction appears in N Engl J Med. 2005;353:1640].  N Engl J Med 2005;353238- 248PubMedGoogle ScholarCrossref
48.
UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet. 1999;354:602].  Lancet 1998;352837- 853PubMedGoogle ScholarCrossref
49.
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.  N Engl J Med 2000;342381- 389[published correction appears in N Engl J Med. 2000;342:1376]PubMedGoogle ScholarCrossref
50.
Nathan  DMCleary  PABacklund  JY  et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.  N Engl J Med 2005;3532643- 2653PubMedGoogle ScholarCrossref
51.
D’Agostino  RB  SrGrundy  SSullivan  LMWilson  PCHD Risk Prediction Group, Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.  JAMA 2001;286180- 187PubMedGoogle ScholarCrossref
52.
Rule  ADLarson  TSBergstralh  EJ  et al.  Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease.  Ann Intern Med 2004;141929- 937PubMedGoogle ScholarCrossref
Original Investigation
September 25, 2006

Cardiovascular Disease Risk Factors in Chronic Kidney Disease: Overall Burden and Rates of Treatment and Control

Author Affiliations

Author Affiliations: National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Mass (Drs Parikh, Hwang, Larson, Levy, and Fox); General Medicine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School (Dr Meigs), Department of Mathematics and Statistics, Boston University (Dr Larson), and Department of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School (Dr Fox), Boston, and National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Md (Drs Hwang, Levy, and Fox).

Arch Intern Med. 2006;166(17):1884-1891. doi:10.1001/archinte.166.17.1884
Abstract

Background  Mild to moderate chronic kidney disease (CKD) is associated with increased risk for cardiovascular disease. The burden of cardiovascular disease risk factors in this setting is not well described.

Methods  We compared the age- and sex-adjusted prevalence of cardiovascular disease risk factors and their treatment and control among persons with and without CKD in 3258 Framingham offspring cohort members who attended the seventh examination cycle (1998-2001). Glomerular filtration rate (GFR) was estimated using the simplified Modification of Diet in Renal Disease Study equation. We defined CKD as a GFR of less than 59 mL/min per 1.73 m2 in women and less than 64 mL/min per 1.73 m2 in men.

Results  Those with CKD were older, more likely to be obese (33.5% vs 29.3%; P=.02), and more likely to have low levels of high-density lipoprotein cholesterol (45.2% vs 29.4%; P<.001) and high triglyceride levels (39.9% vs 29.8%; P<.001). Those with CKD had a higher prevalence of hypertension (71.2% vs 42.7%; P<.001) and hypertension treatment (86.0% vs 72.5%; P<.001), but were less likely to achieve optimal blood pressure control (27.0% vs 45.5%; P<.001). Participants with CKD had a higher prevalence of elevated low-density lipoprotein cholesterol levels (60.5% vs 44.7%; P=.06) and lipid-lowering therapy (57.1% vs 42.6%; P=.09), although this was not statistically significant. A greater proportion of individuals with CKD than those without had diabetes (23.5% vs 11.9%; P=.02) and were receiving diabetes treatment (63.6% vs 46.9%; P=.05), but were less likely to achieve a hemoglobin A1c level of less than 7% (43.8% vs 59.4%; P=.03).

Conclusions  Chronic kidney disease is associated with a significant burden of cardiovascular disease risk factors in the community. The diagnosis of CKD should alert the practitioner to look for potentially modifiable cardiovascular risk factors.

×